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Abstract Edoxaban, a once daily non-vitamin K antag-
onist oral anticoagulant, is a direct, selective, reversible
inhibitor of factor Xa (FXa). In healthy subjects, single
oral doses of edoxaban result in peak plasma concentra-
tions within 1.0–2.0 h of administration, followed by a
biphasic decline. Exposure is approximately dose propor-
tional for once daily doses of 15–150 mg. Edoxaban is
predominantly absorbed from the upper gastrointestinal
tract, and oral bioavailability is approximately 62 %. Food
does not affect total exposure to edoxaban. The terminal
elimination half-life in healthy subjects ranges from 10 to
14 h, with minimal accumulation upon repeat once daily
dosing up to doses of 120 mg. The steady-state volume of
distribution is approximately 107 L, and total clearance is
approximately 22 L/h; renal clearance accounts for
approximately 50 % of total clearance, while metabolism
and biliary secretion account for the remaining 50 %.
Intrinsic factors, such as age, sex and race, do not affect
edoxaban pharmacokinetics after renal function is taken
into account. Oral administration of edoxaban results in
rapid changes in anticoagulatory biomarkers, with peak
effects on anticoagulation markers (such as anti-FXa), the
prothrombin time and the activated partial thromboplastin
time occurring within 1–2 h of dosing.
Key Points
Edoxaban—a highly selective, competitive,
concentration-dependent inhibitor of factor Xa—
rapidly achieves peak plasma concentrations and
exerts its peak effect on anticoagulatory biomarkers.
The drug has high oral bioavailability, and its
clearance involves both renal and non-renal
pathways to almost equal extents.
Coadministration with food does not affect total
edoxaban exposure.
Renal function affects exposure to edoxaban,
but—independently—age, sex and race do not.
1 Introduction
Anticoagulant therapy is commonly used for treatment and
prevention of venous thromboembolism (VTE) [1] and
prevention of stroke in patients with atrial fibrillation (AF)
[2, 3]. The most common standard-of-care treatments
include parenteral heparins and the oral vitamin K antag-
onist warfarin [1, 2].
The anticoagulant effect of warfarin relies on inhibition
of vitamin K-dependent biosynthesis of four coagulation
factors (prothrombin; and factors VII, IX and X) in the
liver [4]. Warfarin has been used for treatment of VTE and
stroke prevention in AF for more than 60 years, but its
therapeutic utility has several limitations. These include a
delayed onset of action, a narrow therapeutic index
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requiring close clinical monitoring of anticoagulation, an
unpredictable and variable pharmacological response, and
numerous drug–drug and food–drug interactions [4, 5].
Non-vitamin K antagonist oral anticoagulants (NOACs)
were developed to inhibit single factors in the coagulation
cascade and with pharmacological properties that over-
come many of the limitations associated with warfarin use.
These NOACs include apixaban, dabigatran, edoxaban and
rivaroxaban.
Edoxaban is an oral, selective, direct and reversible
inhibitor of activated clotting factor X (FXa), the serine
protease responsible for the generation of thrombin (Fig. 1)
[6, 7]. Inhibition of FXa does not interfere with thrombin
activity, which is involved in both coagulation and platelet
activation. The efficacy and safety of edoxaban have been
evaluated in two large phase 3 clinical trials for prevention
of stroke and systemic embolic events in patients with non-
valvular AF [8] and for treatment of deep vein thrombosis
and pulmonary embolism [9]. Edoxaban was found to have
efficacy noninferior to that of warfarin in both trials, with
improved safety, assessed by bleeding events. Edoxaban
60 mg once daily has been approved for use for the above-
mentioned indications in Japan [10], the USA [11],
Switzerland [12] and the European Union [13]. In addition,
edoxaban 30 mg is approved in Japan for prevention of
VTE events in patients undergoing total knee replacement,
total hip replacement or hip fracture surgery [10], on the
basis of the results of three phase 3 trials in respective
patient populations [14–16]. This manuscript reviews the
pharmacokinetic and pharmacodynamic properties of
edoxaban.
2 Physicochemical Properties
Edoxaban is the anhydrous free-drug form, with a molec-
ular mass of 548.06. It is dosed as a monohydrate tosylate
salt, which has a molecular weight of 738.27 [11, 17].
Edoxaban has low solubility in the pH range of 3–7, with a
decrease in solubility with increasing pH [11]. In addition,
its permeability in Caco-2 cells is poor [18], making it a
Biopharmaceutics Classification System class IV com-
pound [19].
3 Pharmacokinetics in Healthy Volunteers
The pharmacokinetics of edoxaban have been studied in
many healthy volunteer studies. Single oral doses of
10–180 mg were administered to healthy subjects.
Fig. 1 Site of edoxaban
modulation in the coagulation
cascade [3]
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Edoxaban exhibits generally linear and dose-proportional
pharmacokinetics [20]. Following oral administration,
edoxaban reaches peak plasma concentration (Cmax) val-
ues within 1–2 h. Edoxaban is widely distributed in the
body, with a steady-state volume of distribution (Vss)
(arithmetic mean ± standard deviation) of 107 ± 19.9 L
[7]. The total clearance of edoxaban is estimated to be
21.8 ± 3.03 L/h, with renal and non-renal clearance
contributing almost equally [7]. Renal clearance is esti-
mated to be about 10.7 ± 3.00 L/h [7]. The terminal
elimination half-life is approximately 10–14 h [11].
Shorter half-lives have been reported in some studies [20,
21]; however, because of a limited sampling duration,
data from these studies should be interpreted with caution.
A summary of the pharmacokinetic parameters of edox-
aban is presented in Table 1.
Multiple-dose administration of once daily doses up to
120 mg results in minimal accumulation (accumulation
ratio of about 1.1) [20], and the pharmacokinetics are linear
and dose proportional—similar to the single-dose phar-
macokinetics (Fig. 2). Steady state is achieved after 3 days
of dosing. Both single- and multiple-dose administration
result in Cmax within 1–2 h after dosing, followed by a
biphasic decline (Fig. 3) [22].
3.1 Absorption
Edoxaban is the active moiety and the predominant cir-
culating drug-related moiety. Oral bioavailability is 62 %
[7]. Edoxaban is primarily absorbed in the upper gas-
trointestinal tract, with approximately 13 % absorbed in
the colon [23]. In a single-dose, food–effect study in
healthy volunteers, the mean peak exposure (Cmax) from a
60 mg dose increased in the fed state by 6–22 %, in
comparison with the fasted state, with a high degree of
individual variability [24]. This variability likely results
from the effect of food on the rate of absorption; the
median tmax (minimum–maximum) increased from 1 h
(0.50–2.50 h) in the fasted state to 1.50 h (0.50–5.0 h) in
the fed state. The effect of food on the total exposure was
minimal and less variable, increasing by 12–15 %, and
was not considered clinically significant [24]. In a healthy
subject study, administration of edoxaban 2 h after
esomeprazole at steady state had no significant effect on
the total exposure, with the 90 % confidence interval (CI)
of the ratio of the least-squares mean being between 80
and 125 %, although the peak exposure decreased by
about 33 % [11].
3.2 Distribution
The disposition of edoxaban is biphasic and is described by
a 2-compartment model [11, 25]. The (mean ± standard
deviation) Vss is 107 ± 19.9 L [11].
3.3 Metabolism, Transport, Protein Binding
and Distribution to Blood
In vitro, five phase 1 edoxaban metabolites were detected
in human liver microsomes: M-1, M-4, M-5, M-6 and a
hydroxylated metabolite at the N,N-dimethylcarbamoyl
group of edoxaban (hydroxymethyl edoxaban) (M-7) [26].
The formation of the human-unique metabolite M-4 is
catalysed by carboxylesterase-1 (CES1) present in human
liver microsomes and in the cytosol [27]. Cytochrome P450
isoenzyme (CYP) 3A4 mediates the formation of M-5 and
hydroxymethyl edoxaban in the presence of nicotinamide
adenine dinucleotide phosphate (NADPH) [26]. M-8, a
minor metabolite, is postulated to arise spontaneously
(non-enzymatically) through an intermediary, hydrox-
ymethyl edoxaban, formed via CYP3A4/5 [21].
In healthy human subjects, six phase 1 metabolites (M-
1, M-2, M-4, M-5, M-6 and M-8) and a glucuronide (M-3)
were detected in plasma (Fig. 4). The human-unique
metabolite M-4 is the major metabolite but is present at
less than 10 % of the total edoxaban exposure in healthy
Table 1 Pharmacokinetic parameters of edoxaban and its major
metabolite, M-4, following a single oral dose administration of
edoxaban 60 mg or intravenous administration of 30 mg dose to
healthy subjects [7]
Parameter Edoxaban; N = 35 M-4; N = 35
Cmax (ng/mL; oral) 256 ± 87.7 18.0 ± 7.97
tmax (h; oral) 1.02 [0.500–3.00] 1.98 [1.48–4.00]
AUC? (ngh/mL; oral) 1766 ± 435.3 128 ± 44.8
t (h; oral) 11.5 ± 5.63 10.5 ± 5.18
CLR (L/h; oral) 9.95 ± 2.32
a Not measured
CL (L/h) 21.8 ± 3.03 NA
Vz (L) 205 ± 64.8 NA
Vss (L) 107 ± 19.9 NA
F ( %) 63.1 ± 12.5 NA
Data are presented as mean ± standard deviation, except for tmax,
which is presented as median [minimum–maximum]
Intravenous administration of edoxaban was used for assessment of
absolute oral bioavailability and true clearance and volume parame-
ters; this formulation is not marketed
AUC? area under the concentration–time curve extrapolated from
time zero to infinity, CL total body clearance, CLR renal clearance,
Cmax maximum observed plasma drug concentration, F absolute
bioavailability, t terminal half-life, tmax time to reach Cmax, Vss
volume of distribution at steady state, Vz volume of distribution based
on the terminal phase
a N = 32
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adults [21]. A summary of the pharmacokinetic parameters
is presented in Table 1. Phase 2 metabolism is mediated by
glucuronidation to form an N-glucuronide metabolite
(M-3). This metabolite has not been quantified. Three of
the metabolites (M-4, M-6 and M-8) have anticoagulant
activity, with half-maximal inhibitory concentration (IC50)
values for anti-FXa of 1.8 nM (M-4), 6.9 nM (M-6) and
2.7 nM (M-8). The IC50 of edoxaban for anti-FXa is 3 nM
[17]. However, because of its low abundance and high
protein binding (80 %), the most abundant metabolite,
M-4, is not expected to contribute significantly to the
overall pharmacological activity of edoxaban in subjects
with at least moderate renal function [28]. Other
metabolites are present in even lower abundance and, in the
absence of CYP inducers, do not contribute significantly to
overall anticoagulant activity (Table 2). None of the
metabolic pathways individually contribute greater than
10 % to total clearance [21].
In vitro bidirectional transport assays in human colon
adenocarcinoma Caco-2 cell monolayers reveal that
edoxaban is a substrate of the efflux transporter P-glyco-
protein (P-gp) but is not a substrate for uptake transporters,
such as organic anion-transporting polypeptide (OATP)
1B1, organic anion transporters (OATs) 1 and 3, or organic
cation transporter (OCT) 2 [18]. Exploratory pharma-
cogenomic analyses demonstrate no effect of the ATP-
Fig. 2 Mean edoxaban plasma
concentration–time profiles
after single-dose administration:
a linear scale and b logarithmic
scale (data on file). The error
bars represent the standard
deviation
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binding cassette, subfamily B, member 1 genotype
(C3435T) on the pharmacokinetics of edoxaban [29].
Edoxaban has a minimal inhibitory effect on CYPs (IC50
C100 lM). It shows a weak inhibitory effect on P-gp,
OATP1B1 and OATP1B3 (IC50 C50 lM), and a minimal
effect on other drug transporters (OAT1, OAT3, OCT1 and
OCT2; IC50C100 lM) [18]. In human hepatocytes, edox-
aban and the metabolites M-4 and M-1 do not induce gene
expression of CYP1A2, CYP3A4 or multidrug resistance
protein 1 (MDR1; P-gp) (data on file). Thus, at clinical
concentrations, edoxaban is unlikely to affect the phar-
macokinetics of other drugs that are substrates of CYPs or
transporters, such as P-gp, OATP1B1, OATP1B3, OAT1,
OAT3, OCT1 or OCT2.
The in vitro total plasma protein binding of edoxaban at
concentrations of 0.2–5 lg/mL is about 55 %, whereas the
human-unique metabolite M-4 is approximately 80 %
bound to plasma proteins over a concentration range of
0.2–2 lg/mL [11, 17]. Edoxaban partitions almost equally
in blood (46 %) and plasma [17].
3.4 Elimination
Edoxaban is primarily eliminated unchanged in urine and
through biliary secretion, with metabolism contributing to a
lesser extent towards total clearance [21] (Fig. 5). Renal
clearance of unchanged drug contributes approximately
50 % to total clearance [7], with the remaining 50 % non-
Fig. 3 Mean edoxaban
concentration–time profiles
after administration of edoxaban
60 mg once daily after a single
dose (day 1; N = 23) or at
steady state (day 4; N = 23):
a linear scale and b logarithmic
scale [22]. The error bars
represent the standard deviation
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renal clearance occurring through metabolism and biliary
secretion. In healthy subjects administered 60 mg of [14C]-
edoxaban, 62 and 35 % of the total radioactive dose was
detected in faeces and urine, respectively. Specifically,
unchanged edoxaban accounted for 49 and 24 % of the
total administered radioactive dose detected in faeces and
urine, respectively [21]. The human-unique metabolite M-4
was detected in small amounts in both urine and faeces, but
was not quantified [21]. The amounts of M-1, M-6 and M-8
in faeces and urine ranged from below the limit of
Fig. 4 Postulated edoxaban metabolism [21]. CES1 carboxylesterase-1, CYP3A4/5 cytochrome P450 isoenzyme 3A4/5, HF human faeces,
HP human plasma, HU human urine, M metabolite, UGT urine 50-diphospho-glucuronosyltransferase














M-4 1.8 *80 5.70 9.02 11.2 12.4
M-6 6.9 NA 2.75 3.69 5.09 4.63
M-8 2.7 NA Not quantifiable at most time points
Edoxaban is *55 % protein bound and has an anti-FXa IC50 value of 3.0 nM
CLCR creatinine clearance, FXa factor Xa, IC50 half-maximal inhibitory concentration, NA not assessed
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quantification to 1.66 and to 1.85 % of total radioactivity,
respectively [21].
Data from bile cannulation studies in rats also suggest
biliary excretion and enterohepatic recirculation (data on
file). Furthermore, mass balance data and pharmacokinetic
data from the oral versus intravenous administration study
[7, 21] indicate biliary excretion of edoxaban. The oral
half-life of edoxaban (10–14 h) [11] suggests distribution
and redistribution resulting in a higher terminal-phase
volume of distribution, possibly due to enterohepatic
recirculation.
3.5 Dose and Time Dependency
A pooled analysis of phase 1 data from five studies—with
doses of 10, 15, 30, 60, 90, 120, 150 and 180 mg—indi-
cates a slightly less-than-dose-proportional dose–exposure
relationship [25]. The population estimate of model-based
relative bioavailability (F1) was found to remain constant
for the dose range of 10–30 mg but decreased with
increasing doses at higher dose levels. For doses above
30 mg, every 30 mg increase in dose was associated with a
6.7 % decrease in F1, presumably due to a decreased dis-
solution rate [25]. This is in line with the absolute
bioavailability of 62 % for a 60 mg oral dose as deter-
mined by Matsushima et al. [7] and thus is not considered
clinically significant.
3.6 Variability
Inter- and intra-subject variability in the clearance and
volume of distribution of edoxaban is low (\30 %) [17].
4 Effects of Intrinsic Factors on Edoxaban
Pharmacokinetics
The effects of various intrinsic factors on the pharma-
cokinetics of edoxaban have been evaluated in many
studies [30–32] and in population pharmacokinetic analy-
ses [11, 33] of patient data. In general, renal function is the
most important intrinsic determinant of total exposure.
Fig. 5 Schematic of clearance pathways for edoxaban in adults. CES-1 carboxylesterase-1, CYP3A4/5 cytochrome P450 isoenzyme 3A4/5
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After accounting for renal function, age is no longer an
independent factor affecting exposure to edoxaban.
Increasing body weight is associated with decreasing
exposure. After accounting for body weight, sex is no
longer an independent determinant of the pharmacokinetics
of edoxaban. Similarly, after accounting for body weight,
edoxaban exposure is similar in Asians and non-Asians
[11, 17]. The data on other racial subgroups are limited.
4.1 Renal Function
Renal clearance is a major component of total clearance of
edoxaban; hence, the pharmacokinetics of edoxaban have
been evaluated in subjects with varying degrees of renal
impairment and normal renal function. The total exposure
to edoxaban increases with increasing degrees of renal
impairment, with 32, 74 and 72 % higher exposure in
subjects with mild [creatinine clearance (CLCR) C50–
B80 mL/min], moderate (CLCR C30–\50 mL/min) and
severe (CLCR \30 mL/min) renal impairment, respec-
tively, versus subjects with normal renal function [31].
Total exposure and peak exposure data are provided in
Table 3. In subjects with end-stage renal disease under-
going peritoneal dialysis, the total exposure is 93 % higher
[31]. Decreasing renal clearance results in higher exposure,
but as renal clearance is only one component of total
clearance, there is a plateauing of the impact of renal
impairment on total clearance. Subjects with moderate and
severe renal impairment have generally similar total
clearance values, despite lower renal clearance (Table 3).
In these subjects, metabolic clearance plays the predomi-
nant role in total clearance of edoxaban.
In subjects with renal impairment, the total exposure to
the metabolites (M-1, M-4, and M-6) increases with
increasing severity of renal impairment. In comparison
with subjects with normal renal function, the total exposure
to edoxaban metabolites in mild, moderate and severe renal
impairment is higher: exposure to M-1 is 1.52-, 2.94- and
5.39-fold higher, respectively; exposure to M-4 is 2.25-,
3.74- and 3.91-fold higher, respectively; and exposure to
M-6 is 1.65-, 2.85- and 2.52-fold higher, respectively (data
on file). The relative abundance of metabolites with respect
to edoxaban increases with the degree of renal impairment.
4.2 Hepatic Function
Impaired hepatic function could alter hepatic metabolism
and affect exposure to edoxaban, as well as blood coagu-
lation. The impact of hepatic function on the single-dose
pharmacokinetics was assessed in subjects with mild and
moderate hepatic impairment and matched healthy controls
[32]. Hepatic impairment did not significantly impact the
peak or total exposure in subjects with mild or moderate
hepatic impairment, consistent with a limited role of hep-
atic metabolism in total clearance of edoxaban.
5 Effects of Extrinsic Factors on Edoxaban
Pharmacokinetics
As previously described, edoxaban is metabolized by CES1
(\10 %), by CYP3A4 (\10 %) and via glucuronidation;
however, metabolism is a minor clearance pathway for
edoxaban in subjects with normal renal function. Hence,
inhibitors or inducers of these enzymes are unlikely to have
a clinically relevant interaction with edoxaban.
Drug interaction studies were nonetheless performed to
investigate the effects of CYP3A4 inhibitors on the phar-
macokinetics of edoxaban. Additionally, the effects of
other drugs that could be dosed concomitantly with edox-
aban were evaluated. Since edoxaban is a substrate of the
efflux transporter P-gp, several drug interaction studies
were conducted with P-gp inhibitors, substrates and
inducers. A summary of the drug interaction studies
exploring the effects of CYP and transporter inhibition/
induction on the pharmacokinetics of edoxaban is pre-
sented in Table 4. The effect of concomitant P-gp inhibitor
use was an increase in exposure to edoxaban [the maxi-
mum observed plasma drug concentration (Cmax) and the
area under the concentration–time curve (AUC)], but the













Cmax (ng/mL) 84.7 ± 26.4 113 ± 48.9 115 ± 42.3 91.9 ± 32.8
AUC? (ngh/mL) 453 ± 102 636 ± 152 816 ± 209 857 ± 199
CLR (L/h) 11.9 ± 1.88 7.68 ± 2.57 4.30 ± 1.72 2.12 ± 0.88
CL/F (L/h) 34.6 ± 7.32 24.8 ± 6.00 19.4 ± 4.69 18.5 ± 4.87
Data are presented as mean ± standard deviation
AUC? area under the concentration–time curve extrapolated from time zero to infinity, CLCR creatinine clearance, Cmax maximum observed
plasma drug concentration
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increase was less than twofold. Drugs that are inhibitors of
P-gp and strong inhibitors of CYP3A4/5 (e.g. ketocona-
zole, erythromycin) did not result in a greater increase in
exposure than drugs that are inhibitors of P-gp and mod-
erate (e.g. verapamil) or mild inhibitors (e.g. cyclosporine)
of CYP3A4/5, thereby reinforcing the fact that metabolism
by CYP3A4/5 is not a major clearance pathway for edox-
aban. These results are summarized below and in Fig. 6.
• Ketoconazole (inhibitor of P-gp transporter; strong
CYP3A4 inhibitor): coadministration of ketoconazole
increased the single-dose peak and total exposure to
edoxaban by 89 and 87 %, respectively [34].
• Quinidine (inhibitor of P-gp and OCT2 transporters;
strong inhibitor of CYP2D6): coadministration of oral
quinidine increased the single-dose peak and 24-h
exposure to orally dosed edoxaban by 85 and 77 %,
respectively [37].
• Orally administered quinidine increased the peak and
total exposure to intravenous edoxaban by 7.5 and
35 %, respectively [7]. Since edoxaban will not be
available as an intravenous formulation, this study
provides mechanistic insight but is not meant for dosing
guidance.
• Verapamil [inhibitor of P-gp (main effect); moderate
inhibitor of CYP3A4]: coadministration of sustained-
release verapamil increased the peak and 24-h exposure
to single doses of edoxaban by 53 % [37].
• Erythromycin (inhibitor of P-gp; moderate CYP3A4
inhibitor): coadministration of erythromycin increased
the peak and total exposure to single doses of edoxaban
by 68 and 85 %, respectively [38].
• Cyclosporine [inhibitor of P-gp, OATP1B1 and breast
cancer resistance protein (BCRP); weak CYP3A4
inhibitor]: coadministration of cyclosporine increased
both the peak and total exposure to single doses of
edoxaban by 74 and 73 %, respectively [39].
• Dronedarone (inhibitor of P-gp): coadministration of
dronedarone increased the peak and total exposure to single
doses of edoxaban by 46 and 85 %, respectively [37].
• Amiodarone (inhibitor of P-gp; moderate CYP2C9
inhibitor, weak CYP2D6 inhibitor): coadministration of
amiodarone, following 3 days of once daily dosing,
increased the peak and total exposure to single doses of
edoxaban by 66 and 40 %, respectively [37]. Amio-
darone has a long half-life of 58 days (range
15–142 days) [40]; the study design was not adequate
to achieve steady-state (or maximal) exposure to
amiodarone [41].
• Rifampin, an inducer of P-gp (strong inducer of
CYP3A4; moderate inducer of CYP2B6, 2C8, 2C9,
2C19; inhibitor of P-gp, OATP1B1, OATP1B3) after
7 days of dosing, decreased total edoxaban exposure by
about 34 %, with no effect on the peak exposure [42].
Other drug interaction study results with potential con-
comitant medications are summarized below and in Fig. 6.
• Digoxin (P-gp substrate): coadministration of digoxin
increased the edoxaban Cmax by 16 %, with no
significant effect on total exposure or renal clearance
at steady state [37].
• Atorvastatin (substrate of OATP1B1 and OATP1B3;
weak inhibitor of CYP3A4): coadministration of
Table 4 Cytochrome P450 isoenzymes (CYPs) and transporters modulated by perpetrator drugs in edoxaban drug–drug interaction (DDI)
studies










DDI with quinidine Quinidine Strong 2D6 P-gp; OCT2
Edoxaban (intravenous) Quinidine Strong 2D6 P-gp; OCT2
DDI with verapamil Verapamil Moderate 3A4; weak 1A2, 2D6 P-gp
DDI with dronedarone Dronedarone Moderate 3A4 P-gp
DDI with ketoconazole Ketoconazole Strong 3A4; weak 2C8, 2C19 P-gp
DDI with erythromycin Erythromycin Moderate 3A4 P-gp
DDI with cyclosporine Cyclosporine Weak 3A P-gp; OATP1B1;
BCRP
DDI with amiodarone Amiodarone Moderate 2C9; weak 2D6, 3A P-gp
DDI with atorvastatin Atorvastatin Weak 3A4
DDI with esomeprazole Esomeprazole 2C9, 2C19 (competitive)
DDI with rifampin Rifampin Strong 3A4; moderate




This table is based on the draft US Food and Drug Administration DDI guidance [35] and the Indiana University DDI table [36]
BCRP breast cancer resistance protein, OATP organic anion-transporting polypeptide, OCT2 organic cation transporter 2, P-gp P-glycoprotein
Clinical PK/PD of Edoxaban 649
atorvastatin with edoxaban had no effect on the peak or
total exposure to edoxaban [37].
• Naproxen: coadministration of naproxen and edoxaban
had no effect on the peak and total exposure to
edoxaban [43]. Coadministration of naproxen and
edoxaban resulted in increased prolongation of bleed-
ing time in comparison with either drug dosed alone.
Coadministration of naproxen increased the baseline-
corrected ratio of bleeding time by 72 % on day 2 in
comparison with edoxaban alone (with a 90 % CI of
139.3–213.3). In contrast, coadministration of edoxa-
ban with naproxen increased the equivalent bleeding
time by 22 % in comparison with naproxen alone (with
a 90 % CI of 98.1–151.0) [43]. Naproxen decreased the
baseline-corrected ratio for platelet aggregation [day 2
ratio (90 % CI): 69.89 % (68.20–71.62)], while edox-
aban did not affect the platelet aggregation effects of
naproxen—the baseline-corrected ratios were compa-
rable for the two treatments [day 2 ratio (90 % CI):
97.20 (94.81–99.64)] (data on file).
• Aspirin: coadministration of high-dose aspirin
(325 mg) increased the steady-state peak and total
exposure to edoxaban by 34 and 30 % [43], respec-
tively, and reduced renal clearance by 17 % (data on
file), possibly because of inhibition of active renal
secretion. Coadministration of low-dose aspirin
(100 mg) did not affect the peak or total exposure to
edoxaban either after single-dose administration or at
steady state, as the 90 % CIs were entirely contained
within the 80–125 % bounds [43]. Coadministration of
edoxaban and low-dose (100 mg) or high-dose aspirin
(325 mg) resulted in an additive effect on the prolonga-
tion of bleeding time [43]. The anticoagulant effects of
edoxaban were not affected by coadministration of
aspirin. Coadministration of low-dose aspirin (100 mg)
did not significantly affect the prothrombin time (PT),
international normalized ratio (INR), activated partial
thromboplastin time (aPTT) or intrinsic FX activity [43].
• Enoxaparin: enoxaparin did not affect the peak and
total exposure to edoxaban when dosed concomitantly
or 12 h apart. Coadministration of edoxaban 60 mg and
subcutaneous enoxaparin 1 mg/kg resulted in an
increased effect on thrombin generation assay param-
eters in comparison with either drug dosed alone [44].
The effect, in general, was not additive, with the
exception of the thrombin generation lag time and time
to peak. The effect on anti-FXa, when both drugs were
coadministered, appeared to be additive [44].
Fig. 6 Summary of edoxaban
drug interaction studies results
[11]. The triangles represent the
geometric least-squares mean
ratio of the maximum observed
plasma drug concentration
(Cmax) when edoxaban was
dosed alone or with the test
drug, the squares represent the
geometric least-squares mean
ratio for the area under the
concentration–time curve
(AUC) and the horizontal bars
represent the 90 % confidence
interval. P-gp P-glycoprotein
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• Esomeprazole, a proton pump inhibitor, which
increases gastric pH to approximately 5 after multiple
doses, increased the Cmax of edoxaban dosed with a 2-h
stagger at steady state by approximately 33 % (90 % CI
57.98–78.07), while the total exposure was within the
80–125 % CI [11], demonstrating no significant effect
on the total exposure (data on file). A previous study
demonstrated no significant effect on the peak and total
exposure with concurrent dosing [45]. Of note, the
dissolution and solubility of edoxaban are pH depen-
dent; hence, in patients with achlorhydria or other
conditions (or concomitant use of drugs) that increase
stomach pH above 6, the rates of solubility and
dissolution of edoxaban may be reduced, thereby
affecting total absorption of edoxaban.
6 Pharmacology and Pharmacodynamics
Serine protease FXa binds coagulation factor Va on the
surface of activated platelets and forms a prothrombinase
complex, which subsequently converts prothrombin to
thrombin [46]. FXa is the primary site of prothrombin
amplification and thus constitutes an attractive target for
anticoagulant treatment (Fig. 1). Edoxaban is a selective
and competitive inhibitor of human FXa, with an inhibitory
constant (Ki) value of 0.561 nM [6]. It inhibits the gener-
ation of thrombin and formation of blood clots in a dose-
dependent manner.
Edoxaban produces rapid anticoagulation with a direct
concentration–effect relationship. Within 1–2 h after sin-
gle-dose administration to healthy subjects, maximum
dose-proportional effects of edoxaban 10–150 mg on
plasma anti-FXa activity were observed, concurrent with
the edoxaban Cmax [20]. Plasma edoxaban concentrations
are linearly related to anti-FXa activity in healthy subjects
(Fig. 7). A similar linear relationship was observed in
patients with VTE and AF.
Intrinsic FX activity data from a phase 2 study of
patients with AF [47] were modelled. Using a logistic
regression model and breakpoint or threshold concepts, it
was demonstrated that the duration of intrinsic FX sup-
pression exceeding a threshold—as opposed to the actual
magnitude of suppression—correlated with bleeding risk
[47]. The model identified the most significant predictor for
bleeding as the period of time during which intrinsic FX
activity was maintained at 15 % or less. Prolonged sup-
pression below this threshold accounted for more bleeding
observed in the phase 2 study, where, despite the same
total daily dose from a 60 mg once daily regimen versus a
30 mg twice daily regimen, the 30 mg twice daily regimen
resulted in more bleeding [48, 49]; the 30 mg twice daily
regimen suppressed intrinsic FX activity for 18.8 h, while
the 60 mg once daily regimen led to 13.7 h of intrinsic FX
activity suppression [47].
In the Badimon Perfusion-Chamber model, a single
60 mg dose of edoxaban in healthy subjects markedly
reduced ex vivo thrombus formation under high and low
Fig. 7 Observed anti-factor Xa
(anti-Fxa) activity versus
plasma edoxaban concentration
after administration of a single
60 or 180 mg dose in healthy
subjects (data on file)
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shear rates, consistent with anti-FXa activity [50]. Also in
healthy subjects, a shed blood model showed significant
inhibition of thrombin generation and platelet activation by
edoxaban at single doses of 30, 60 and 120 mg [51]. A
nadir for shed blood levels of prothrombin fragments 1 ? 2
(F1?2) and for platelet activation-marker b-thromboglob-
ulin were achieved at 1.5 h postdose, whereas placebo had
minimal suppressive effects. The anticoagulant effects of
edoxaban were sustained for 24 h [51]. In a study of elderly
healthy subjects, in addition to producing anti-FXa activity
and reducing F1?2, edoxaban 60 mg twice daily induced a
thrombin generation lag time and inhibited the peak and
constant velocity indices. There was no evidence of a
rebound effect following cessation of dosing [52].
Other coagulation markers affected by edoxaban include
PT and aPTT. In healthy subjects treated with edoxaban
60 mg daily for 4 days, PT and aPTT reached peak ele-
vations within 2 h and returned to near-baseline levels
within 24 h, both after a single dose (day 1) and after
multiple doses (day 4) [53]. However, modest magnitudes
of change and variability make none of these tests ideal for
routine and consistent clinical assessment of drug effects.
7 Cardiovascular Safety
The effect of edoxaban on cardiac polarization was eval-
uated in an active and placebo-controlled ‘thorough QTc’
[54] study of supratherapeutic doses of 90 and 180 mg in
healthy subjects [55]. Edoxaban did not have a threshold
pharmacological effect on cardiac repolarization. The
upper bounds of the 95 % one-sided CIs for the least-
squares mean of the placebo-corrected QTc interval (QTcI)
change from time-matched baseline did not exceed 4 ms at
any time point after dosing of either dose. The absolute
value of QTcI did not exceed 450 ms for any subject on
either dose of edoxaban, and all except one subject had
changes in QTcI that were below 30 ms at all time points
[17, 55]. One subject in the 90 mg edoxaban dose group
had a change in QTcI value of 32 ms at 10 h postdose. No
clinically relevant changes in electrocardiogram wave-
forms were noted with edoxaban treatment. A positive
correlation between plasma concentrations and change in
QTcI was not observed up to edoxaban concentrations of
857 ng/mL [55].
8 Switching
Edoxaban is the fourth entrant into the marketplace, and
patients might switch from other anticoagulants to edoxa-
ban. On the basis of the single-dose pharmacokinetics of
edoxaban and pharmacodynamic effects, which generally
parallel the plasma concentration–time profiles, it appears
that switching from other anticoagulants to edoxaban is
feasible at the next scheduled dosing time of the prior
treatment. This maintains adequate anticoagulation. Thus,
switching from warfarin to edoxaban 24 h after cessation
of warfarin therapy maintains continued anticoagulation
with no effect of warfarin on the pharmacokinetics of
edoxaban [56]. Similarly, switching from enoxaparin to
edoxaban could be performed at the next scheduled dosing
time for enoxaparin [44]. For patients receiving unfrac-
tionated heparin, it is recommended that edoxaban is
started 4 h after stopping the heparin infusion [11].
The effects of switching from the other NOACs to
edoxaban on edoxaban pharmacokinetics and pharmaco-
dynamics have also been studied. A single oral dose of
edoxaban 60 mg administered on day 4, following
administration of once daily rivaroxaban 20 mg for 3 days,
resulted in pharmacokinetic parameters similar to those of
continual treatment with edoxaban [22]. Anticoagulant
effects after switching from rivaroxaban to edoxaban, as
assessed by assays such as anti-FXa, PT, aPTT and
endogenous thrombin potential (ETP), were also similar to
those after 4 days of continual edoxaban treatment [53].
Similar results were obtained after switching to edoxaban
60 mg after 3 days of dosing with apixaban 5 mg twice
daily [17]. Finally, edoxaban pharmacokinetic parameters
were similar after switching from dabigatran 150 mg twice
daily for 3 days to an edoxaban 60 mg single dose, com-
pared with 4 days of continual treatment with edoxaban
alone [22]. Upon analysis of anticoagulant effects, mea-
surements of aPTT and ETP suggested a carryover effect of
dabigatran on anticoagulation, although PT and anti-FXa
activities were not different between subjects who switched
treatment from dabigatran and those who received contin-
uous treatment with edoxaban alone [53]. Thus, switching
from rivaroxaban or dabigatran to edoxaban could also be
performed at the next scheduled time of dosing.
Appropriate transitioning from edoxaban to warfarin can
be likely achieved by maintaining optimal anticoagulation
via two options: by coadministration of a parenteral anti-
coagulant and warfarin after cessation of edoxaban dosing
until INR C2.0, at which time parenteral anticoagulation
can be stopped, or by coadministration of a 50 % lower
dose of edoxaban along with warfarin until INR C2.0, at
which time the reduced dose of edoxaban can be stopped.
With either option, INR should be checked weekly [11,
57]. To switch from edoxaban to another NOAC, admin-
istration of the NOAC should begin at the next scheduled
dose of edoxaban [11]. Clinical evaluation of this scheme,
as patients transitioned off blinded edoxaban or warfarin to
the open-label anticoagulant, minimized the number of
major bleeding and stroke events during the 30 days of
posttrial follow-up [57].
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9 Summary and Conclusion
Edoxaban—a highly selective, competitive, concentration-
dependent inhibitor of FXa—exhibits rapid achievement of
Cmax and peak effects on biomarkers such as PT, aPTT and
anti-FXa. It has high oral bioavailability, and its clearance
mechanisms involve both renal and non-renal pathways to
almost equal extents. P-gp inhibitor drugs increase the total
exposure to less than twofold, while CYP3A4 inhibition
causes a minimal additional change in exposure. Admin-
istration of food with edoxaban does not affect total
exposure. Renal function affects exposure to edoxaban,
but—independently—age, sex and race do not. Edoxaban
concentrations have been shown to have a linear correla-
tion with anti-FXa activity. Although edoxaban has active
metabolites, because of their low abundance, they are
unlikely to contribute significantly to anticoagulant activity
in most patients.
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